MULTIPLE-DOSE ACTIVATED-CHARCOAL AND ENHANCEMENT OF SYSTEMIC DRUG CLEARANCE - SUMMARY OF STUDIES IN ANIMALS AND HUMAN VOLUNTEERS

被引:19
作者
CHYKA, PA [1 ]
机构
[1] UNIV TENNESSEE,MEMPHIS,TN 38163
来源
JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY | 1995年 / 33卷 / 05期
关键词
ACTIVATED CHARCOAL; POISONING; DRUG ELIMINATION; REVIEW; DIALYSIS; PHARMACOKINETICS;
D O I
10.3109/15563659509013748
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Multiple-dose activated charcoal therapy can enhance the systemic elimination of many drugs. Studies in animals and human volunteers provide a framework for understanding the indications and limitations of multiple-dose activated charcoal therapy. Enterocapillary exsorption creates a compartment for diffusion of drugs out of the bloodstream and activated charcoal can augment this process to enhance drug clearance. Once charcoal reaches the intestine, there is a rapid onset of action. Clearance at exsorption sites is limited by blood flow, moreover, the rate of exsorption is related to the dose of charcoal up to a ceiling dose. Drug absorption, distribution, metabolism and elimination dynamically interact with multiple-dose activated charcoal therapy making it difficult to identify a single variable that may predict the success or failure with this therapy. Drug characteristics associated with enhanced systemic clearance with multiple-dose activated charcoal include a low intrinsic clearance, presence in the body for a sufficient time period for charcoal to act, a prolonged distributive phase, non-restrictive protein binding, and a small volume of distribution. Drugs that are unaffected at low doses may respond to multiple doses of activated charcoal when nonlinear kinetics are apparent due to overdose or disease. Although our current understanding is incomplete, multiple-dose activated charcoal therapy will play a role in the future therapy of poisoning patients.
引用
收藏
页码:399 / 405
页数:7
相关论文
共 28 条
[1]   THE EFFECT OF ACTIVATED-CHARCOAL ON MOUSE SLEEP TIMES INDUCED BY INTRAVENOUSLY ADMINISTERED HYPNOTICS [J].
ADLER, LJ ;
WATERS, DH ;
GWILT, PR .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1986, 7 (05) :421-429
[2]  
ARIMORI K, 1989, CHEM PHARM BULL, V37, P3148
[3]   ACCELERATION OF THE BODY CLEARANCE OF PHENOBARBITAL BY ORAL ACTIVATED-CHARCOAL [J].
BERG, MJ ;
BERLINGER, WG ;
GOLDBERG, MJ ;
SPECTOR, R ;
JOHNSON, GF .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (11) :642-644
[4]  
CALDWELL JH, 1980, ARCH PHARM, V312, P271
[5]   PHYSICOCHEMICAL CHARACTERISTICS OF DRUGS AND RESPONSE TO REPEAT-DOSE ACTIVATED-CHARCOAL [J].
CAMPBELL, JW ;
CHYKA, PA .
AMERICAN JOURNAL OF EMERGENCY MEDICINE, 1992, 10 (03) :208-210
[6]   CORRELATION OF DRUG PHARMACOKINETICS AND EFFECTIVENESS OF MULTIPLE-DOSE ACTIVATED-CHARCOAL THERAPY [J].
CHYKA, PA ;
HOLLEY, JE ;
MANDRELL, TD ;
SUGATHAN, P .
ANNALS OF EMERGENCY MEDICINE, 1995, 25 (03) :356-362
[7]  
CROME P, 1977, LANCET, V2, P1203
[8]  
DEVRIES MH, 1989, J PHARM PHARMACOL, V41, P528
[9]  
FARRAR HC, 1993, CRIT CARE MED, V21, P29
[10]   THE EFFECT OF ORAL ACTIVATED-CHARCOAL ON THE SYSTEMIC CLEARANCE OF GENTAMICIN IN RABBITS WITH ACUTE-RENAL-FAILURE [J].
HASAN, MM ;
ELSAYED, YM ;
ABDELAZIZ, AA .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1990, 42 (02) :85-88